Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial

Park, Keunchil; ÖZGÜROĞLU, Mustafa; Vansteenkiste, Johan; Spigel, David; Yang, James; Ishii, Hidenobu; Garassino, Marina; de Marinis, Filippo; Szczesna, Aleksandra; Polychronis, Andreas; Uslu, Ruchan; Krzakowski, Maciej; Lee, Jong-Seok; Calabro, Luana; Frontera, Osvaldo; Xiong, Huiling; Bajars, Marcis; Ruisi, Mary; Barlesi, Fabrice

doi:10.1016/j.jtho.2021.03.009

Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial

Park K., ÖZGÜROĞLU M., Vansteenkiste J., Spigel D., Yang J. C. H., Ishii H., ...Daha Fazla

JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.8, ss.1369-1378, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 16 Sayı: 8
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.jtho.2021.03.009
Dergi Adı: JOURNAL OF THORACIC ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.1369-1378
Anahtar Kelimeler: Avelumab, PD-L1, Non-small cell lung cancer, Second-line, Phase 3, OPEN-LABEL, NIVOLUMAB, MULTICENTER
İstanbul Üniversitesi Adresli: Hayır

Özet

Introduction: In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data.